Skip to main content
SpringerLink
Log in

Highlights in the adjuvant treatment of colon cancer from annual meetings 2011

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

The new biologic drugs that are active in the advanced setting of colon cancer have failed when used in the adjuvant setting. Both bevacizumab (NSABP C-08, AVANT-trial) and cetuximab (NO147 trial) added to oxaliplatin-based chemotherapy demonstrated no improvements in 3-year DFS compared with chemotherapy alone. However, subgroup analysis of the NO147 trial indicated that irinotecan and cetuximab might have a synergistic effect and the combination of FOLFIRI and cetuximab led to an improvement in 3-year DFS and 2-year OS compared with FOLFIRI alone. The encouraging results of this small patient cohort have to be confirmed by prospective trials. The use of adjuvant chemotherapy in stage II colon cancer remains controversial. Fluoropyrimidine-based chemotherapy should be discussed in high-risk stage II patients. The addition of oxaliplatin to fluoropyrimidine shows a trend toward improvement in DFS and OS at 5 years in patients with high-risk stage II colon cancer. In our opinion, this combination should be applied only in exceptional cases such as younger patients with accumulation of risk factors. Prognostic classifier like ColoPrint might identify high-risk patients who will benefit from chemotherapy on the basis of gene expression information in the primary tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27;3109–16.

    Article  PubMed  Google Scholar 

  2. Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combinded with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer. Results from NSABP C-07. J Clin Oncol. 2007;25:2198–2204.

    Article  CAS  PubMed  Google Scholar 

  3. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with flurouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.

    Article  CAS  PubMed  Google Scholar 

  4. QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisol, higher dose folinic acid or both as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet. 2000;355:1588–96.

    Article  Google Scholar 

  5. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II randomized trial comparing bevacizumab plus fluorouracil/leucovorin with FU/LV in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–5.

    Article  CAS  PubMed  Google Scholar 

  6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

    Article  CAS  PubMed  Google Scholar 

  7. Saltz L, Diaz-Rubio E, Scheithauer W, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.

    Article  CAS  PubMed  Google Scholar 

  8. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.

    Article  CAS  PubMed  Google Scholar 

  9. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Overall survival of patients with KRAS wild-type tumors treated with FOLFOX4 ± Cetuximab as 1st-line treatment for metastatic colorectal cancer: the Opus study. ECCO-ESMO. 2009 (Abstract No. 6.079).

  10. Douillard JY, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–4705.

    Article  CAS  PubMed  Google Scholar 

  11. Peeters M, et al. Randozmized phase III study of Panitumumab with fluorouracil, leucovorin and irinotectan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:4706–13.

    Article  CAS  PubMed  Google Scholar 

  12. Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol. 2011; 29:11–6.

    Article  CAS  PubMed  Google Scholar 

  13. Allegra CJ, Yothers GA, O’Connell MJ, et al. Overall survival and updated disease-free survival results of the NSABP C-08 trial assessing bevacizumab in stage II and III colon cancer. J Clin Oncol. 2011;29 (ASCO Annual Meeting Abstracts, Abstract 3508).

  14. André T, Van Cutsem E, Schmoll HJ, et al. A multinational, randomized phase III study of bevacizumab with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer: results and subgroup analyses from the AVANT trial. J Clin Oncol. 2011;29 (ASCO Annual Meeting Abstracts, Abstract 3509).

  15. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc Am Soc Clin Oncol. 2004;23:246 (Abstract 3500)

    Article  Google Scholar 

  16. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27:3117–25.

    Article  CAS  PubMed  Google Scholar 

  17. Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2 + Irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009;20:674–80.

    Article  CAS  PubMed  Google Scholar 

  18. Huang J, Sargent DJ, Mahoney MR, et al. Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147. Gastrointest Cancer Symp. 2011;28:18 (Abstract 363).

    Google Scholar 

  19. Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer : Results from NCCTG intergroup phase III trial N0147. J Clin Oncol. 2010;28:262 (Abstract CRA3507).

    Article  Google Scholar 

  20. Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011;29:17–24.

    Article  PubMed  Google Scholar 

  21. Rosenberg R, Maak M, Simon I, et al. Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer patients. J Clin Oncol. 2011;29 (Abstract 358).

  22. Yothers GA, Allegra CJ, O’Connell MJ, et al. The efficacy of oxaliplatin when added to 5-flurouracil/leucovorin in stage II colon cancer. J Clin Oncol. 2011;29 (ASCO Annual Meeting Abstracts, Abstract 3507).

Download references

Conflict of interest

The authors declare that there is no current or potential conflict of interest in relation to this article.

Author information

Authors and Affiliations

  1. Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Grieskirchnerstraße 42, 4600, Wels, Austria

    Gudrun Resch MSc, MD &  Josef Thaler MD

Authors
  1. Gudrun Resch MSc, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josef Thaler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gudrun Resch MSc, MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Resch, G., Thaler, J. Highlights in the adjuvant treatment of colon cancer from annual meetings 2011. memo 5, 163–166 (2012). https://doi.org/10.1007/s12254-012-0018-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-012-0018-z

Keywords

Search

Navigation